Gene therapy strategies for Duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors.
Gene transfer vectors based on adeno-associated virus (AAV) are now widely used in the field of gene therapy. These vectors have been studied for their potential use in treating many diseases, among them the muscular dystrophies, the most common of which is Duchenne muscular dystrophy (DMD). Several recent advances in the areas of AAV serotype analysis, transgene engineering, and vector delivery to muscle, together with novel means of rescuing mutant mRNA transcripts, have yielded impressive results in animal models of DMD. This minireview focuses on these recent advances and their implications for potential treatments for DMD and other neuromuscular disorders.
Blankinship
Michael J
MJ
Department of Neurology, Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center, University of Washington, Seattle, 98195-7720, USA.
Gregorevic
Paul
P
Chamberlain
Jeffrey S
JS
D004274:DNA, Recombinant / Q000008:administration & dosage / Q000627:therapeutic use; D000229:Dependovirus / Q000235:genetics*; D016503:Drug Delivery Systems / Q000379:methods*; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D020388:Muscular Dystrophy, Duchenne / Q000235:genetics* / Q000628:therapy*
D004274:DNA, Recombinant